Skip to content
AnalystLens

ResMed 8-K Report, Financial Results (Jan 29, 2026)

Reports
Earnings & Results·Other Events·Exhibits & Filings
Filing Date
Filed January 29, 2026
Period End
January 29, 2026
Securities
RMDRSMDF
In the record · 2016–202610-K1410-Q338-K85

RMD filed 14 annual reports (10-K), 33 quarterly reports (10-Q) and 85 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Jul ’19Jul ’19
  3. Leadership change8-K · Jul ’22Jul ’22
  4. Leadership change8-K · Aug ’24Aug ’24

01—Abstract

Summary

Summary of the 8-K filed January 29, 2026. Cited figures are marked; the original filing is the authoritative source.

ResMed Inc. reported results for the second quarter of fiscal year 2026, the quarter ended December 31, 2025, in Exhibit 99.1 furnished with this 8-K.

Revenue rose 11% to $1,422.8 milliona (up 9% on a constant currency basis), compared with $1,282.1 million a year earlier. Gross margin was 61.8%, up 320 basis points, and non-GAAP gross margin was 62.3%, up 310 basis points, driven by manufacturing and logistics efficiencies and component cost improvements. Income from operations increased 18% to $491.7 million, and non-GAAP income from operations increased 19% to $517.2 million.

Net income was $392.6 millionb, with diluted earnings per share of $2.68 (non-GAAP diluted EPS of $2.81). Operating cash flow for the quarter was $339.7 million. SG&A expenses rose 15% to $278.4 million, or 19.6% of revenue versus 18.8% a year earlier, mainly due to VirtuOx acquisition costs, employee costs, and marketing and technology investments.

The company recorded $5.9 millionc of restructuring expenses tied to workforce planning undertaken in the first quarter. Cash and cash equivalents were $1,417.1 million at December 31, 2025, while short-term debt rose to $259.9 million from $9.9 million at June 30, 2025, and long-term debt fell to $403.9 million from $658.4 million.

During the quarter the company paid $87.6 milliond in dividends and repurchased 704,000 shares for $175.0 million. Separately, the board declared a quarterly cash dividend of $0.60 per share, with a record date of February 12, 2026, payable March 19, 2026, and an ex-dividend date of February 11, 2026 for common stockholders and CDI holders.

02—Key points

Key Highlights

  1. Revenue increased 11% year over year to $1,422.8 million, or 9% on a constant currency basis.
  2. Gross margin expanded 320 basis points to 61.8%; non-GAAP gross margin expanded 310 basis points to 62.3%.
  3. Income from operations rose 18% to $491.7 million; non-GAAP income from operations rose 19% to $517.2 million.
  4. Diluted EPS was $2.68 versus $2.34 a year earlier; non-GAAP diluted EPS was $2.81 versus $2.43.
  5. Operating cash flow was $339.7 million for the quarter, compared with $308.6 million a year earlier.
  6. SG&A rose 15% to $278.4 million, or 19.6% of revenue, partly due to the VirtuOx acquisition.
  7. Declared a quarterly cash dividend of $0.60 per share, with a record date of February 12, 2026 and payment on March 19, 2026.

03—Questions

Frequently Asked Questions

  1. How did ResMed perform in the second quarter of fiscal 2026?

    Revenue grew 11% to $1,422.8 million (9% on a constant currency basis). Income from operations grew 18% and non-GAAP income from operations grew 19%. Diluted EPS was $2.68, and non-GAAP diluted EPS was $2.81.

  2. What drove the improvement in gross margin?

    The filing attributes the 320 basis point increase in gross margin primarily to manufacturing and logistics efficiencies and component cost improvements, with non-GAAP gross margin up 310 basis points due to the same factors.

  3. What were the main drivers of higher operating expenses?

    SG&A increased 12% on a constant currency basis, mainly due to expenses associated with the VirtuOx acquisition, employee costs, and marketing and technology investments. SG&A was 19.6% of revenue versus 18.8% a year earlier. The company also recorded $5.9 million of restructuring charges from workforce planning undertaken in the first quarter.

  4. What are the key dividend dates for shareholders?

    The quarterly dividend of $0.60 per share has an ex-dividend date of February 11, 2026, a record date of February 12, 2026, and a payment date of March 19, 2026. CDI holders on the Australian Securities Exchange will receive an equivalent amount in Australian currency.

  5. How much capital did ResMed return to shareholders and what is its cash position?

    During the quarter, ResMed paid $87.6 million in dividends and repurchased 704,000 shares for $175.0 million. Cash and cash equivalents were $1,417.1 million at December 31, 2025, and short-term debt was $259.9 million.

04—Continue

← View all 8-K filings